NCT03650491 - A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma With Failed Remission

Interventions

DRUG

FOR46

FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46

Trial Locations (7)

Icahn School of Medicine at Mt. Sinai, New York

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore

Winship Cancer Institute, Emory University, Atlanta

Karmanos Cancer Institute, Detroit

Washington University in St. Louis-Siteman Cancer Center, St Louis

University of Colorado Cancer Center, Aurora

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco